Triastek 3DµS - Model MR - 3D Microstructure for Modified Release
The 3DμS-MR platform represents a significant advancement in drug delivery technology, specifically designed to meet challenging pharmaceutical requirements. It is characterized by its ability to optimize the release behavior of drugs in vivo through intricate structural designs enabled by material science. This platform is instrumental in accelerating the research and development process by offering a versatile environment for the development of complex drug formulations. 3DμS®-MR's unique structure allows for the fine-tuning of drug release rates, enhancing the bioavailability of challenging molecules and improving overall drug efficacy. The released 3DμS®-MR V2.0 version expands its application scenarios, facilitating drug product design and development to an even greater extent, while the forthcoming V3.0 version is expected to address critical clinical needs, making it suitable for various new application scenarios. The ultimate aim is to increase productivity in the pharmaceutical industry by offering a robust solution to drug delivery issues.
Accelerate R&D Process
Incorporating an X-ray imaging agent enables more accurate tracking of drug delivery and release in the Gl tract. The accumulated experience in material science study and structural design enables the creation of various in vivo drug release behaviors, thereby providing an efficient development platform for complexformulations.
Improve Drug Efficacy
Well controlled programmed release enables accurate drug release at the desired time and Gl location with a desired rate. 3DμS®-MR platform is particularly suited to meeting unmet clinical needs for the drugs requiring sustained release, pulsatile release or those with a narrow therapeutic window.
Improve the drugability of challenging molecules.
Increase Productivity
The convenient MED 3D printing continuous manufacturing process offers lower costs and ensures more consistent quality for complex formulations.
- 3DμS-MR V1.0 meets the clinical needs for most of the drugs.
- 3DμS-MR V2.0 further expands application scenarios, meets challenging drug delivery needs, facilitates drug product design and development.
- 3DμS-MR V3.0 will be further developed to address more critical clinical needs, making it suitable for more diverse application scenarios.
3DμS-MR comprises a delay layer and a drug-containing core. Featuring innovative structures, 3DμS-MR platform enables various release profile, including delayed release, immediate release, extended release, pulsed release, etc.